COST EFFECTIVENES ANALYSIS OF RANIBIZUMAB COMPARED TO AFLIBERCEPT AND LASER INTERVENTION IN TREATMENT OF DIABETIC MACULAR EDEMA (DME) IN THE CZECH REPUBLIC

被引：1
|
作者：
Klimes, J. [1 ]
Regnier, S. A. [2 ]
Mahon, R. [3 ]
Budek, T. [1 ]
Dostal, F. [1 ]
Skalicky, D. [1 ]
Depta, J. [4 ]
机构：
[1] Novartis Sro, Prague, Czech Republic
[2] Novartis Pharmaceut, Basel, Switzerland
[3] Novartis Global Business Serv, Dublin, Ireland
[4] Novartis Pharma AG, Basel, Switzerland
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.549
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS25
引用
收藏
页码：A419 / A419
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS ANALYSIS OF INTRAVITREAL AFLIBERCEPT VERSUS RANIBIZUMAB IN THE TREATMENT OF DIABETIC MACULAR EDEMA (DME) UNDER THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM (SUS)
    Rosim, M. P.
    Riveros, B. S.
    Kim, H. S.
    Nakada, C.
    Freire, W. R.
    VALUE IN HEALTH, 2018, 21 : S426 - S426
  • [2] COST-EFFECTIVENESS OF INTRAVITREAL AFLIBERCEPT VERSUS RANIBIZUMAB IN THE TREATMENT OF DIABETIC MACULAR EDEMA IN SPAIN
    Granell Villalon, M.
    Riera, M.
    Boixadera, A.
    Villacampa, A.
    Mondejar, J.
    Deschaseaux, C.
    VALUE IN HEALTH, 2018, 21 : S428 - S428
  • [3] Aflibercept versus ranibizumab for diabetic macular edema: A meta-analysis
    Chen, Haiyan
    Shi, Xuehui
    Zhang, Wang
    Han, Qianqian
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2024, 34 (03) : 615 - 623
  • [4] COST-EFFECTIVENESS ANALYSIS OF INTRAVITREAL AFLIBERCEPT VERSUS LASER PHOTOCOAGULATION AND RANIBIZUMAB IN THE TREATMENT OF VISUAL IMPAIRMENT DUE TO DIABETIC MACULAR EDEMA IN CHINA
    Ming, J.
    Zhang, Y.
    Xu, X.
    Zhao, M.
    Wang, Y.
    Chen, Y.
    Zhang, F.
    Wang, J.
    Liu, J.
    Zhao, X.
    Han, R.
    Hu, S.
    VALUE IN HEALTH, 2019, 22 : S580 - S580
  • [5] Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema
    Demircan, Ali
    Alkin, Zeynep
    Yesilkaya, Ceren
    Demir, Gokhan
    Kemer, Burcu
    JOURNAL OF OPHTHALMOLOGY, 2018, 2018
  • [6] Treatment of Diabetic Macular Edema with Aflibercept in Eyes with Previous Nonresponse to Ranibizumab and/or Bevacizumab
    Sadowsky, Rachel
    Quiram, Polly
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [7] Transitioning from Aflibercept to Biosimilar Ranibizumab in Diabetic Macular Edema (DME): (The TRANSFORM-DME Trial) a Multicenter Observational Study
    Chakraborty, Debdulal
    Sinha, Tushar Kanti
    Maiti, Aniruddha
    Boral, Subhendu Kumar
    Das, Arnab
    Mondal, Soumen
    Nandi, Krishnendu
    Bhattacharya, Ranabir
    CLINICAL OPHTHALMOLOGY, 2024, 18 : 3449 - 3456
  • [8] Prognostic factors in the treatment of diabetic macular edema (DME) using aflibercept, ranibizumab and bevacizumab (DRCR.net protocol T)
    Schmidt-Erfurth, Ursula
    Bogunovic, Hrvoje
    Schlegl, Thomas
    Sadeghipour, Amir
    Waldstein, Sebastian M.
    Gerendas, Bianca
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [9] The Cost-Effectiveness of Ranibizumab for the Treatment of Diabetic Macular Edema
    Brown, Gary C.
    Brown, Melissa M.
    Turpcu, Adam
    Rajput, Yamina
    OPHTHALMOLOGY, 2015, 122 (07) : 1416 - 1425
  • [10] Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment
    Sonja G. Karst
    Jan Lammer
    Christoph Mitsch
    Manuela Schober
    Janhvi Mehta
    Christoph Scholda
    Michael Kundi
    Katharina Kriechbaum
    Ursula Schmidt-Erfurth
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256 : 49 - 58
12345